Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06953778 · ClinicalTrials.gov registry record · NA
The Effectiveness of Patch-Based Screening for Pre-Symptomatic Atrial Fibrillation to Improve Patient Outcome
A NA study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- NA
- Development phase
- 24,060
- Enrollment target
NCT06953778: Clinical Trial NA study, sponsored by VA Office of Research and Development.
NCT06953778 is a NA study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 24,060 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1615% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06953778, a NA study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 24,060 participants
- Enrollment target
Study Summary
* The goal of the screening trial is to determine whether early screening for atrial fibrillation improves outcomes, including lowering the chance of death, hospitalization for stroke, blood clots, heart failure, heart attack, and severe bleeding reduces the risk of stroke or heart failure. * Atrial fibrillation is a common heart condition in which one of the heart chambers doesn't follow a normal rhythm. Blood clots can form as a result, and they can travel to the brain and cause strokes, or to other organs. * Almost everyone with atrial fibrillation is treated with drugs called anticoagulants ("blood thinners") to reduce the risk of stroke. These drugs also increase the risk of bleeding. * Testing for atrial fibrillation is usually done for patients who have symptoms of an irregular or unusually fast or slow heartbeat, often called "palpitations" or a sensation of the heart pounding or stopping for a short period of time. * What is not known is whether screening people who do not have symptoms of atrial fibrillation, but who are at above-average risk of getting atrial fibrillation, will reduce death, hospitalization for stroke, blood clots, heart failure more than it increases hospitalization for severe bleeding. * People who participate in the trial who are selected by chance to receive screening will wear a small heart-rate monitor (Zio Patch) on their skin for 14 days and then return it to the manufacturer. Their doctors will be notified about the results and will make decisions about any treatment to recommend. * The screening trial is expected to enroll about 24,000 VA patients nationwide and to last 7 years, but each person's active participation in the trial is completed after sending in the Zio Patch. After that, the study team will just collect information from the participant's electronic medical records.
Primary Outcome
Hospitalization for stroke, as determined by ICD-10 codes associated with hospitalization. The primary outcome is time to the first event of stroke, systemic embolism, heart failure, acute coronary syndrome, or major bleeding, or death from any cause (outcomes 1-6).
Interventions
- DEVICE Zio XT® Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24,060 participants |
| Start Date | 2027-03-08 |
| Est. Completion | 2033-10-03 |
| Phase | NA |
What is known before NCT06953778 opens enrollment
NCT06953778 is an interventional study that assigns participants to a tested intervention. Its 24,060 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1615% higher).
The record links to 0 conditions, and to 1 intervention - of which Zio XT® Patch is the first listed.
NCT06953778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06953778 about?
NCT06953778 is a clinical study titled "The Effectiveness of Patch-Based Screening for Pre-Symptomatic Atrial Fibrillation to Improve Patient Outcome". * The goal of the screening trial is to determine whether early screening for atrial fibrillation improves outcomes, including lowering the chance of death, hospitalization for stroke, blood clots, heart failure, heart attack, and severe bleeding reduces the risk of stroke or heart failure. * Atrial...
What is the current status of trial NCT06953778?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 24,060 participants. The study started on 2027-03-08. Estimated completion is 2033-10-03.
What interventions are being tested in trial NCT06953778?
The interventions under investigation include: Zio XT® Patch (DEVICE).
Who is sponsoring clinical trial NCT06953778?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06953778's enrollment target sits among peer trials
24,060 10th of 2000 higher than 1,991 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06995898 · 24,000 participants · NA
The Vanguard Study: Testing a New Way to Screen for Cancer
- NCT04595201 · 25,000 participants
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
- NCT04994015 · 25,000 participants
Parkinson's Foundation PD GENEration Genetic Registry
- NCT06589310 · 25,000 participants
Falcon Real World Evidence Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI